FINWIRES · TerminalLIVE
FINWIRES

$INCY

38 stories mentioning INCYUpdated 3d ago

Every FINWIRES story that references INCY, newest first.

What are analysts saying about INCY?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on INCY?

Wire

Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program

Incyte (INCY) said Thursday that Minjuvi, a treatment for relapsed or refractory follicular lymphoma, is being funded in Ontario through the province's Funding Accelerated for Specific Treatments, or FAST program.The program enables eligible patients to gain access to the treatment sooner while formal reimbursement processes continue, the company said.Price: $125.89, Change: $-0.13, Percent Change: -0.10%

$INCY
Research

Canaccord Genuity Initiates Incyte at Buy With $152 Price Target

Incyte (INCY) has an average rating of overweight and mean price target of $128.91, according to analysts polled by FactSet.

$INCY
Insider Trading

Incyte Insider Sold Shares Worth $1,296,792, According to a Recent SEC Filing

Pablo J Cagnoni, President, Global Head of R&D, on August 12, 2026, sold 10,803 shares in Incyte (INCY) for $1,296,792. Following the Form 4 filing with the SEC, Cagnoni has control over a total of 194,001 common shares of the company, with 194,001 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000120570326000027/xslF345X05/wk-form4_1786737658.xml

$INCY
Insider Trading

Incyte Insider Sold Shares Worth $273,646, According to a Recent SEC Filing

Patrick A Mayes, Executive Vice President & Chief Scientific Officer, on August 05, 2026, sold 2,207 shares in Incyte (INCY) for $273,646. Following the Form 4 filing with the SEC, Mayes has control over a total of 61,441 common shares of the company, with 61,441 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000207996226000015/xslF345X05/wk-form4_1786132914.xml

$INCY
Insider Trading

Incyte Insider Sold Shares Worth $1,305,422, According to a Recent SEC Filing

Pablo J Cagnoni, President, Global Head of R&D, on August 05, 2026, sold 10,640 shares in Incyte (INCY) for $1,305,422. Following the Form 4 filing with the SEC, Cagnoni has control over a total of 204,804 common shares of the company, with 204,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000120570326000025/xslF345X05/wk-form4_1786132939.xml

$INCY
Wire

Mizuho Adjusts Price Target on Incyte to $137 From $121

Incyte (INCY) has an average rating of overweight and mean price target of $126, according to analysts polled by FactSet.Price: $119.22, Change: $-0.30, Percent Change: -0.25%

$INCY
Wire

Top Midday Gainers

Kiniksa Pharmaceuticals International (KNSA) reported Tuesday a Q2 net income and sales above market expectations.Separately, Wedbush said in a report the firm is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes.Shares surged 23% as intraday trading volume grew to over 1.9 million from a daily average of about 734,000.IQVIA (IQV) reported a year-over-year increase in Q2 adjusted earnings and revenue, and raised its 2026 outlook.Shares jumped 12%, with intraday trading volume rising to more than 3.3 million from a daily average of about 1.6 million.Incyte (INCY) on Tuesday reported Q2 non-GAAP earnings and sales above market expectations, and raised net sales guidance for 2026.Shares climbed up 8% amid a surge in intraday trading volume to over 3.3 million from a daily average of about 1.7 million.Price: $78.52, Change: $+14.98, Percent Change: +23.58%

$INCY$IQV$KNSA
Wire

Oppenheimer Raises Incyte Price Target to $120 From $107

Incyte (INCY) has an average rating of overweight and mean price target of $117.52, according to analysts polled by FactSet.Price: $130.20, Change: $+11.33, Percent Change: +9.53%

$INCY
Wire

Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept

Incyte (INCY) has an average rating of overweight and mean price target of $117.52, according to analysts polled by FactSet.Price: $129.07, Change: $+10.20, Percent Change: +8.58%

$INCY
Wire

Wells Fargo Adjusts Price Target on Incyte to $116 From $101

Incyte (INCY) has an average rating of overweight and mean price target of $117.52, according to analysts polled by FactSet.Price: $125.70, Change: $+6.83, Percent Change: +5.75%

$INCY
Wire

BofA Securities Raises Incyte Price Target to $136 From $124

Incyte (INCY) has an average rating of overweight and mean price target of $115.29, according to analysts polled by FactSet.Price: $111.69, Change: $-3.19, Percent Change: -2.78%

$INCY
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) fell 1.4%.In corporate news, Conmed (CNMD) shares jumped 9% after Bloomberg Law reported that the company is exploring options including a potential sale amid takeover interest from private equity firms.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.5%.Humana (HUM) shares gained 4.1% after Wells Fargo upgraded the company's stock to overweight from equal-weight and increased the price target to $502 From $227.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares rose 3.3%, and Incyte was down 1.5%.

$CNMD$COAG$HUM$INCY$KVUE
Sectors

Sector Update: Healthcare Stocks Higher Monday Afternoon

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index rising 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) fell 1.6%.In corporate news, a federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.4%.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares gained 6.5%, and Incyte was down 1.8%.Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. Its shares rose 1.6%.

$COAG$INCY$KVUE$NAGE
Wire

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a Monday note.The investment firm said in the research note that HMB-002 is particularly well suited for Type 1 patients, who comprise about 75% of the diagnosed Von Willebrand disease population, because it targets restoration of the underlying von Willebrand factor.The analysts noted that HMB-002 has demonstrated encouraging preliminary clinical efficacy, with eight of nine evaluable patients experiencing no treated bleeding events during the 28 days following a single dose.Multidose Part B data expected in late 2026 or early 2027 should provide the first assessment of whether the early efficacy observations translate into durable bleed reduction with chronic dosing, according to the note.Wedbush reiterated its outperform rating and $55 price target on the stock.Shares of Hemab were up 2% in Monday trading.Price: $38.79, Change: $+0.75, Percent Change: +1.99%

$COAG$INCY
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) marginally higher and the iShares Biotechnology ETF (IBB) down 0.1%.ACADIA Pharmaceuticals (ACAD) stock was up nearly 10% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.Incyte (INCY) shares were up 1.8% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Opzelura cream for adults with moderate atopic dermatitis.Avalo Therapeutics (AVTX) will be added to the small-cap Russell 2000 index and the broad-market Russell 3000 index, effective after market close Friday. Shares of Avalo Therapeutics were up more than 1% pre-bell.

$ACAD$AVTX$IBB$INCY$XLV
Wire

UBS Adjusts Price Target on Incyte to $113 From $103

Incyte (INCY) has an average rating of overweight and mean price target of $112.05, according to analysts polled by FactSet.Price: $109.26, Change: $+0.80, Percent Change: +0.74%

$INCY
Wire

Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept

Incyte (INCY) has an average rating of overweight and mean price target of $111.95, according to analysts polled by FactSet.Price: $102.32, Change: $+4.10, Percent Change: +4.17%

$INCY
Research

BMO Capital Upgrades Incyte to Market Perform From Underperform, Adjusts PT to $94 From $75

Incyte (INCY) has an average rating of overweight and mean price target of $111.95, according to analysts polled by FactSet.

$INCY
Research

William O'Neil Initiates Incyte at Buy

Incyte (INCY) has an average rating of overweight and mean price target of $110.82, according to analysts polled by FactSet.

$INCY
Wire

HC Wainwright Adjusts Incyte Price Target to $140 From $135, Maintains Buy Rating

Incyte (INCY) has an average rating of overweight and mean price target of $109.57, according to analysts polled by FactSet.Price: $103.10, Change: $+2.46, Percent Change: +2.44%

$INCY

Showing 1-20 of 38

Track with the FINWIRES app suite

FolioX
FolioX
Track INCY in your portfolio
WheelAI
WheelAI
Analyze INCY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on INCY